Table 3.
Results of LCA for ADRIATIC lung cancer trial
| Category | Activity | Carbon (tCO2e) | Contribution |
| Study team | Facilities | 838 | 51.14% |
| Staff commuting | 70 | 4.29% | |
| Study drug impact | IP and placebo | 33 | 2.03% |
| Patient journey | Patient visits | 11 | 0.67% |
| Patient communication materials | 0.4 | 0.02% | |
| Sample life cycle | Global biobank storage | 1.1 | 0.06% |
| Samples for analysis and storage | 44 | 2.68% | |
| Pregnancy tests | 0.1 | 0.00% | |
| Testing kits | 14 | 0.84% | |
| Other procured services (third-party vendors) | Documentation and communication | 14 | 0.87% |
| Data management | 18 | 1.09% | |
| Device, software and online tools | 90 | 5.47% | |
| Other services | 5.5 | 0.33% | |
| Trial devices and software | ePRO devices | 95 | 5.78% |
| Procedures | MRI scans | 51 | 3.10% |
| CT scans | 9.4 | 0.57% | |
| Other diagnostics (X-ray, ECG, bone and PET scans) | 0.9 | 0.05% | |
| Investigator and trial site management | Site monitor visits (and audits) | 68 | 4.17% |
| Trial site utilities | 26 | 1.61% | |
| Investigator and support staff commuting | 15 | 0.90% | |
| Global trial management | Global investigator meetings | 77 | 4.73% |
| Global monitor meetings | 18 | 1.11% | |
| IRB/IEC meetings (486 local f2f IEC meetings, 306 virtual) | 139 | 8.47% | |
| Data monitoring committee meetings and global study team meetings | ND | ND | |
| Total | 1638 | 100% | |
| Per randomised patient (kg of CO2e) | 2452 |
CO2e, carbon dioxide equivalent; ePRO, electronic patient-reported outcome; IP, investigational product; IRB/IEC, independent review board/independent ethical committee; LCA, life cycle assessment; PET, Positron emission tomography.